2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. Published online December 12, 2023. doi:10.1056/NEJMoa2312054
2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. Published online December 12, 2023. doi:10.1056/NEJMoa2312054 (声明:文中图片来源于网络共享,如涉及侵权请联系作者删除处理) ...
Daratumumab (Dara), a monoclonal antibody directed against CD38, is highly effective in treating myeloma and improves response rates and progression free survival (PFS) when added to PI or IMiD. Ixazomib, lenalidomide and dexamethasone (IRd) is an effective, all oral, induction regimen that has ...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Daratumumab in multiple myeloma. PMID: 30951198 Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. PMID: 34087126
Daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved by the FDA in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Darzalex Faspro-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are considered eligible for autolo...
89%的患者对来那度胺耐药,71%的患者对硼替佐米(bortezomib)耐药,64%的患者对硼替佐米和来那度胺耐药。 参考文献: [1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网...
as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20...
日前,强生旗下杨森制药与欧洲骨髓瘤网络(EMN)合作报告了3期临床研究APOLLO(MMY3013)的结果。该研究评估了daratumumab(达雷木单抗,Darzalex)皮下(SC)剂型联合pomalidomide(泊马度胺)和dexamethasone(地塞米松)(简称Pd)对比单独使用Pd,用于复发或难治性多发性骨髓瘤(MM)患者的有效性和安全性,这些患者曾接受过lenalidomide(...
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaAuthor(s): Pieter Sonneveld 1 , Meletios A. Dimopoulos 1 , Mario Boccadoro 1 , Hang Quach 1 , P. Joy Ho 1 , Meral Beksac 1 , Cyrille Hulin 1 , Elisabetta Antonioli 1 , Xavier Leleu 1 , Silvia Mangiacavalli ...